US2021162055A1PendingUtilityA1
Modified release formulations containing drug-ion exchange resin complexes
Est. expiryMar 16, 2026(expired)· nominal 20-yr term from priority
A61K 31/192A61P 25/04A61K 31/135A61K 31/485A61K 9/1664A61K 9/2081A61K 31/155A61K 47/6933A61K 31/4458A61K 31/137A61K 9/2077A61K 9/1635A61K 47/50A61K 31/24A61K 9/0056A61K 9/10A61K 9/5026A61K 47/32A61K 9/0095A61K 9/2027A61K 31/4402A61K 47/14A61K 31/216A61K 9/2013A61P 25/26A61K 9/0053A61K 9/5021A61K 45/06A61K 47/6927A61K 9/4866A61K 9/2031A61K 9/14A61K 47/6921A61K 9/167A61K 9/16A61K 47/585A61K 9/48
79
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
An aqueous liquid suspension containing a coated drug—ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine—ion exchange resin complex is provided. The coated amphetamine—ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described.
Claims
exact text as granted — not AI-modified1 . A modified release coated drug—ion exchange resin complex useful in preparing modified release pharmaceutical composition, said complex comprising a drug bound to a pharmaceutically acceptable ion exchange resin and having a high tensile strength water-permeable, water-insoluble, modified release polymeric barrier coating over the drug—ion exchange resin complex.
2 . A method of treating a patient in need thereof with a pharmaceutically active drug having a modified release profile, said method comprising orally delivering a composition according to claim 1 .Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.